![Twitter](images/entities/453/resize_twitter.jpg)
http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
-
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
-
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
-
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
-
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
-
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx (ARDX) Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
-
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
-
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
-
Ardelyx (ARDX) Granted FDA Orphan Drug Designation for XPHOZAH
-
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
-
Ardelyx (ARDX) Announces Resignation of Geoffrey Block from Board
-
Ardelyx Announces Departure of Board Member
-
Ardelyx to Participate at the Jefferies London Healthcare Conference
-
Ardelyx (ARDX) Announces XPHOZAH now Available in the US
-
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
-
Ardelyx (ARDX) Reports Positive Data from Studies of XPHOZAH
-
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
-
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx (ARDX) Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG
-
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
-
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
-
Ardelyx (ARDX) Announces SLR Capital Partners to Provide $50M of Additional Committed Capital
-
Ardelyx (ARDX) Announces FDA Approval of XPHOZAH
-
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
-
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
-
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
-
Ardelyx (ARDX) Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients
-
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
-
Ardelyx (ARDX) Announces Publication of Positive Results from T3MPO-3 Trial of Tenapanor
-
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
-
Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan
-
Tenapanor for Hyperphosphatemia Approved in Japan
-
Ardelyx (ARDX) Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA for IBS-C
-
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
-
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance